肝硬化难治性腹水的诊治与血管收缩药物的应用

doi:10.3969/j.issn.1672-5069.2015.05.004

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (5): 460-462.doi: 10.3969/j.issn.1672-5069.2015.05.004

肝硬化难治性腹水的诊治与血管收缩药物的应用

肖丽，杨玲

430022 武汉市华中科技大学同济医学院附属协和医院消化内科

收稿日期:2015-06-29 出版日期:2015-09-10 发布日期:2016-02-18
通讯作者: 杨玲，E-mail：hepayang@163.com E-mail:984107325@qq.com
作者简介:肖丽，E-mail：984107325@qq.com

Application of vasoconstrictors in management of patients with refractory ascites

Xiao Li，Yang Ling

Division of Gastroenterology，Department of Internal Medicine，Union Hospital，Huazhong University of Science& Technology，Wuhan 430022， China

Received:2015-06-29 Online:2015-09-10 Published:2016-02-18
Contact: Yang Ling，E-mail:hepayang@163.com E-mail:984107325@qq.com

摘要/Abstract

关键词: 肝硬化, 难治性腹水, 腹腔穿刺大量放液术, 血管收缩药物

Key words: Cirrhosis, Refractory ascites, Paracentesis, Vasoconstrictors

肖丽，杨玲. 肝硬化难治性腹水的诊治与血管收缩药物的应用[J]. 实用肝脏病杂志, 2015, 18(5): 460-462.

Xiao Li，Yang Ling. Application of vasoconstrictors in management of patients with refractory ascites[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 460-462.

[1] D'Amico G，Garcia-Tsao G，Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol，2006，44（1）:217-231.
[2] Planas R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol，2006，4（11）:1385-1394.
[3] Ochs A. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med，1995，332（18）:1192-1197.
[4] Runyon BA. Management of adult patients with ascites due to cirrhosis:an update. Hepatology，2009，49（6）:2087-2107.
[5] EASL clinical practice guidelines on the management of ascites，spontaneous bacterial peritonitis，and hepatorenal syndrome in cirrhosis. J Hepatol，2010，53（3）:397-417.
[6] Moore KP. Guidelines on the management of ascites in cirrhosis. Gut，2006，55（suppl_6）:vi1-vi12.
[7] Gines P. Management of cirrhosis and ascites. N Engl J Med， 2004，350（16）:1646-1654.
[8] Singhal S. Management of refractory ascites. Am J Ther，2012， 19（2）:121-132.
[9] Moore KP. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology，2003，38（1）:258-266.
[10] Lenz K. Treatment and management of ascites and hepatorenal syndrome:an update. Therap Adv Gastroenterol，2015，8（2）:83-100.
[11] Singh V. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. Am J Gastroenterol，2013，108（4）:560-567.
[12] Singh V. Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. J Hepatol，2012，56（2）:348-354.
[13] Sola-Vera J. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology，2003，37（5）:1147-1153.
[14] Singh V. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics:a randomized pilot study. Am J Gastroenterol，2008，103（6）:1399-1405.
[15] Kalambokis G. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol， 2007，46（2）: 213-221.
[16] Hamdy H. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients:a randomized pilot study. J Clin Gastroenterol，2014，48（2）:184-188.
[17] Singh V. Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. J Hepatol，2012，56（2）:348-354.
[18] Fimiani B. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function:A multicentric study. Eur J Intern Med，2011，22（6）:587-590.
[19] Singh V. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis:a randomized study. J Gastroenterol Hepatol，2006，21（1 Pt 2）:303-307.
[20] Lenaerts A. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol，2005，29（11）:1137-1142.
[21] Schrier RW. Tolvaptan，a selective oral vasopressin V2-receptor antagonist，for hyponatremia. N Engl J Med，2006，355（20）: 2099-2112.
[22] Cardenas A. Tolvaptan， an oral vasopressin antagonist，in the treatment of hyponatremia in cirrhosis. J Hepatol，2012，56（3）: 571-578.
[23] Okita K. A multicenter，open-label，dose-ranging study to exploratively evaluate the efficacy，safety，and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol，2010，45（9）:979-987.
[24] Wong F. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut，2012，61（1）:108-116.
[25] Bureau C.Serum bilirubin and platelet count:a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol，2011，54（5）:901-907.
[26] Gaba RC.Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites:a single institution case-control propensity score analysis. Clin Radiol，2015，70（5）: e51-7.

肝硬化难治性腹水的诊治与血管收缩药物的应用

Application of vasoconstrictors in management of patients with refractory ascites

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[4]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[5]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[6]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[7]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[8]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[9]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[10]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[11]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[12]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[13]	陈山, 庄华帅, 邢诒喜, 吴直佳. 美罗培南治疗肝硬化并发上消化道出血患者对感染预防和再出血的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 704-707.
[14]	徐祺林, 郝少欢, 冉博. 肝硬化脾切除术后门静脉系统血栓形成的危险因素分析*[J]. 实用肝脏病杂志, 2019, 22(5): 708-711.
[15]	金良红, 李兴杰, 关红博, 麻少辉. 双能量CT碘定量结合动态对比增强MRI评估肝硬化患者肝脏血流动力学和肝功能临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 712-715.